only

Quarterly Update

January 2022

use

ersonal

PAINCHEK LTD

PHILIP DAFFAS,

CEO & MD

ASX:PCK

CORPORATE OVERVIEW

ersonal use only

PainChek provides Software-As-A-Service that uses AI for the detection of patient pain via video analysis

  • Targeting enterprise customers who have patients with an inability to communicate pain levels (e.g. dementia)

Technology is clinically & commercially validated, has key regulatory approvals & is unique

  • Multiple peer reviewed publications & clinical trials - 90% + concordance to existing methods
  • Adult and Infant Apps regulatory cleared for sale in Australia, Europe, UK, NZ, Singapore & Canada, FDA in progress
  • Patent granted in US, Japan, Australia and China - awaiting grants in Europe - protection until 2037

Large global markets - now in global commercialization phase based on strong Australia take up

  • Over 1,500 aged care facilities & ~125,000 beds already signed up to SaaS contracts in Australia - ~60% market share
  • UK sales accelerating with NZ and Singapore underway
  • 80-85% long term gross margins & recurring revenue each month
  • Multiple new products scheduled for launch over next 2 years to drive further growth (B2C dementia, infant/toddler)

Better outcomes for patients & enterprise customers

  • Improved patient care - more targeted treatments & better outcomes
  • Improves efficiency - saves customers money - less data entry/labour, less adverse patient events

2 |

ersonal use only

Our purpose is to

give a voice to

people who

cannot reliably

verbalise their pain

3 |

THE INITIAL SIZE OF THE PROBLEM

ersonal use only

400M25-42%

pre-verbal children

of hospital beds occupied

by people with dementia

57M

people living with

dementia

>150M expected by

2050

  1. Ecology Communications Group. www.ecology.com/birth-death-rates
  2. World Alzheimer Report 2016
  3. Germossa et al. BMC Nursing (2019) 18:40
  4. Tsai, I. P., Jeong, S. Y. S., & Hunter, S. (2018). Pain assessment and management for older patients with dementia in hospitals: an integrative literature review. Pain Management Nursing, 19(1), 54-71
  5. Lancet Public Health - January 2022

4 |

PAINCHEK STRATEGIC PILLARS FOR 2022

ersonal use only

CORE RAC

MARKET

EXPANSION

  • Implement 120,000 contracted beds across ANZ and transition to standard PCK contracts - targeting $5.5m ARR
  • Expansion of UK beds licences & integrations
  • Establish broader market position in NZ, Singapore & Canada

FOCUS ON

COMMERCIALISATION OF

INFANT APP

  • Initial target markets:
    • Post vaccination initial focus
    • Health care professionals & home consumers
    • Global therapeutic partnerships
  • Potential as key tool in COVID-19 vaccinations
  • Large market opportunity in regulatory cleared overseas markets

STRATEGIC NEW

PRODUCT & GLOBAL

MARKET ENTRIES

  • Build Home Care & Hospital business model & sales in ANZ
  • Establish disability market entry model
  • Leverage ANZ learnings in UK & other overseas markets
  • Submit FDA de novo clinical study
  • Establish market entry model & partnerships for EU & Asia

5 |

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

PainChek Limited published this content on 28 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2022 00:25:01 UTC.